These findings suggest that PON and ASC bind with ABL1, ABL2, and mutated ABL1 and ABL2 proteins that are reported to mediate cardiovascular toxicity in CML patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.